These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16097885)

  • 1. Structural proteomics in drug discovery.
    Tari LW; Rosenberg M; Schryvers AB
    Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural genomics-impact on biomedicine and drug discovery.
    Weigelt J
    Exp Cell Res; 2010 May; 316(8):1332-8. PubMed ID: 20211166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focusing in on structural genomics: the University of Queensland structural biology pipeline.
    Puri M; Robin G; Cowieson N; Forwood JK; Listwan P; Hu SH; Guncar G; Huber T; Kellie S; Hume DA; Kobe B; Martin JL
    Biomol Eng; 2006 Dec; 23(6):281-9. PubMed ID: 17097918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ATCG of drug discovery.
    Fernandes PB
    Curr Opin Mol Ther; 2000 Dec; 2(6):624-32. PubMed ID: 11249739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When will the genomics investment pay off for antibacterial discovery?
    Mills SD
    Biochem Pharmacol; 2006 Mar; 71(7):1096-102. PubMed ID: 16387281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industrial perspective on X-ray data collection and analysis.
    Skarzynski T; Thorpe J
    Acta Crystallogr D Biol Crystallogr; 2006 Jan; 62(Pt 1):102-7. PubMed ID: 16369099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel drug discovery and molecular biological methods, via DNA, RNA and protein changes using structure-function transitions: Transitional structural chemogenomics, transitional structural chemoproteomics and novel multi-stranded nucleic acid microarray.
    Gagna CE; Lambert WC
    Med Hypotheses; 2006; 67(5):1099-114. PubMed ID: 16828979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics technology and therapeutics.
    Hong ML; Jiang N; Gopinath S; Chew FT
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):563-8. PubMed ID: 16700895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovering novel ligands for macromolecules using X-ray crystallographic screening.
    Nienaber VL; Richardson PL; Klighofer V; Bouska JJ; Giranda VL; Greer J
    Nat Biotechnol; 2000 Oct; 18(10):1105-8. PubMed ID: 11017052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics and proteomics in process development: opportunities and challenges.
    Gupta P; Lee KH
    Trends Biotechnol; 2007 Jul; 25(7):324-30. PubMed ID: 17475353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated technologies and novel techniques to accelerate protein crystallography for structural genomics.
    Manjasetty BA; Turnbull AP; Panjikar S; Büssow K; Chance MR
    Proteomics; 2008 Feb; 8(4):612-25. PubMed ID: 18210369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural proteomics by NMR spectroscopy.
    Shin J; Lee W; Lee W
    Expert Rev Proteomics; 2008 Aug; 5(4):589-601. PubMed ID: 18761469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome annotating proteomics pipelines: available tools.
    Shadforth I; Bessant C
    Expert Rev Proteomics; 2006 Dec; 3(6):621-9. PubMed ID: 17181476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modelling of drug targets: the past, the present and the future.
    Dahl SG; Sylte I
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):151-5. PubMed ID: 15733208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.